Bactrim®
Trimethoprim / Sulfamethoxazole · oral tablet
Antibiotic
Approved uses
Urinary tract infection, acute otitis media, acute exacerbation of chronic bronchitis, shigellosis, Pneumocystis pneumonia, travelers' diarrhea
Adults: 1 DS tablet (800 mg/160 mg) or 2 BACTRIM tablets PO q12h. Children 2 months and older: 40 mg/kg/day sulfamethoxazole with 8 mg/kg/day trimethoprim divided q12h. Pneumocystis treatment: 75 to 100 mg/kg/day sulfamethoxazole with 15 to 20 mg/kg/day trimethoprim divided q6h for 14 to 21 days. Pneumocystis prophylaxis: adults 1 DS tablet daily; children 750 mg/m2/day sulfamethoxazole with 150 mg/m2/day trimethoprim divided twice a day on 3 consecutive days per week.
OFF-LABELNot in the FDA label for this product
Preseptal cellulitis or eyelid abscess, MRSA suspected or culture-proven
1600 mg/320 mg (2 DS tablets) PO BID x 7 days, the regimen used in the drained-abscess trial
RCT · n=1247 · indirect
No trial has studied preseptal cellulitis specifically. In 1247 patients with a drained uncomplicated skin abscess (45.3% MRSA-positive), clinical cure was 80.5% versus 73.6% with placebo (difference 6.9 percentage points, 95% CI 2.1 to 11.7); ocular and periocular MRSA isolates remain largely susceptible, with 8.7% resistance among 399 culture-positive ocular and periocular MRSA cases in a northern California pediatric series.
Nonpurulent cellulitis, MRSA coverage added to a cephalosporin
320 mg/1600 mg PO BID x 7 days added to cephalexin 500 mg PO QID x 7 days
RCT · no added benefit
Adding it to cephalexin for uncomplicated nonpurulent cellulitis did not raise cure rates: 83.5% versus 85.5% per protocol (difference -2.0 percentage points, 95% CI -9.7 to 5.7, P = .50). Enrollment excluded abscess, wound, and purulent drainage, and the authors noted the modified intention-to-treat estimate was imprecise and did not exclude a clinically important benefit.
Prophylaxis of recurrent toxoplasmic retinochoroiditis
One tablet, trimethoprim 160 mg with sulfamethoxazole 800 mg, PO every 3 days for up to 20 months
RCT · n=124 · open-label
In 124 patients with a history of recurrent toxoplasmic retinochoroiditis randomized to this regimen or to observation, recurrence occurred in 4 of 61 treated (6.6%) versus 15 of 63 untreated (23.8%), P = .01, over up to 20 months. The trial was open-label with no placebo arm, and a Cochrane review graded the recurrence reduction as moderate-quality evidence but found no good evidence of a visual acuity benefit (low-quality, 93 participants, mean difference -1.00 letters, 95% CI -7.93 to 5.93), noting that absence of evidence of effect is not the same as evidence of no effect.
Contraindications
- Known hypersensitivity to trimethoprim or sulfonamides
- History of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides
- Documented megaloblastic anemia due to folate deficiency
- Pediatric patients less than 2 months of age
- Marked hepatic damage
- Severe renal insufficiency when renal function status cannot be monitored
- Concomitant administration with dofetilide
800 mg/160 mg DS tablets, 400 mg/80 mg tablets, bottles of 100
Sulfamethoxazole blocks bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, and trimethoprim reversibly inhibits dihydrofolate reductase, the next enzyme in the pathway. Together they block two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria, and in vitro resistance develops more slowly than with either component alone.
Warnings & Precautions
- Embryofetal Toxicity: Some epidemiologic studies suggest that exposure to BACTRIM during pregnancy may be associated with an increased risk of congenital malformations, particularly neural tube defects, cardiovascular malformations, urinary tract defects, oral clefts, and club foot. If BACTRIM is used during pregnancy, or the patient becomes pregnant while taking it, advise her of the potential hazards to the fetus.
- Hypersensitivity and Other Serious or Fatal Reactions: Fatalities and serious adverse reactions, including SCARs (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, AFND, AGEP), fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias, acute and delayed lung injury, anaphylaxis and circulatory shock have occurred with sulfamethoxazole and trimethoprim products, including BACTRIM.
- Management of Hypersensitivity Reactions: BACTRIM should be discontinued at the first appearance of skin rash or any sign of a serious adverse reaction, because a skin rash may be followed by a more severe reaction. Rash, pharyngitis, fever, arthralgia, cough, chest pain, dyspnea, pallor, purpura or jaundice may be early indications of serious reactions.
- Hypersensitivity Reactions of the Respiratory Tract: Cough, shortness of breath and pulmonary infiltrates potentially representing hypersensitivity reactions of the respiratory tract have been reported in association with sulfamethoxazole and trimethoprim treatment.
- Respiratory Failure: Other severe pulmonary adverse reactions occurring within days to week of BACTRIM initiation and resulting in prolonged respiratory failure requiring mechanical ventilation or ECMO, lung transplantation or death have also been reported, including in otherwise healthy individuals.
- Circulatory Shock: Circulatory shock with fever, severe hypotension, and confusion requiring intravenous fluid resuscitation and vasopressors has occurred within minutes to hours of re-challenge in patients with recent (days to weeks) exposure to sulfamethoxazole and trimethoprim.
- Hemophagocytic Lymphohistiocytosis: Cases of HLH, a life-threatening syndrome of pathologic immune activation, have been reported; signs may include fever, hepatosplenomegaly, rash, lymphadenopathy, neurologic symptoms, cytopenias, high serum ferritin, hypertriglyceridemia, and liver enzyme and coagulation abnormalities. If HLH is suspected, discontinue BACTRIM immediately and institute appropriate management.
- Streptococcal Infections and Rheumatic Fever: The sulfonamides should not be used for treatment of group A β-hemolytic streptococcal infections; in an established infection, they will not eradicate the streptococcus and will not prevent sequelae such as rheumatic fever.
- Thrombocytopenia: BACTRIM-induced thrombocytopenia may be an immune-mediated disorder, and severe cases that are fatal or life threatening have been reported. Thrombocytopenia usually resolves within a week upon discontinuation of BACTRIM.
- Clostridioides difficile Associated Diarrhea: CDAD has been reported with nearly all antibacterial agents, including BACTRIM, and may range in severity from mild diarrhea to fatal colitis. It has been reported over two months after antibacterial use; if CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
- Risk Associated with Concurrent Use of Leucovorin: Treatment failure and excess mortality were observed when BACTRIM was used with leucovorin for P. jirovecii pneumonia in HIV positive patients. Avoid coadministration of BACTRIM and leucovorin during treatment of P. jirovecii pneumonia.
- Development of Drug Resistant Bacteria: Prescribing BACTRIM in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit and increases the risk of drug-resistant bacteria.
- Folate Deficiency: Avoid use of BACTRIM in patients with impaired renal or hepatic function, possible folate deficiency (e.g., the elderly, chronic alcoholics, anticonvulsant therapy, malabsorption syndrome, malnutrition states), severe allergies or bronchial asthma. Hematological changes indicative of folic acid deficiency may occur in elderly patients or in patients with preexisting folic acid deficiency or kidney failure, and these effects are reversible by folinic acid therapy.
- Hemolysis: In glucose-6-phosphate dehydrogenase deficient individuals, hemolysis may occur. This reaction is frequently dose-related.
- Hypoglycemia: Cases of hypoglycemia in non-diabetic patients are seen rarely, usually after a few days of therapy; patients with renal dysfunction, liver disease, malnutrition or high doses of BACTRIM are particularly at risk. BACTRIM potentiates the effect of oral hypoglycemics metabolized by CYP2C8 or CYP2C9 or eliminated renally via OCT2, and additional monitoring of blood glucose may be warranted.
- Porphyria and Hypothyroidism: Like other drugs containing sulfonamides, BACTRIM can precipitate porphyria crisis and hypothyroidism. Avoid use of BACTRIM in patients with porphyria or thyroid dysfunction.
- Potential Risk in AIDS Patients: AIDS patients may not tolerate or respond to BACTRIM in the same manner as non-AIDS patients, and rash, fever, leukopenia and elevated aminotransferase values have been reported to be increased during treatment of P. jirovecii pneumonia. If any sign of adverse reaction develops, reevaluate benefit-risk of continuing therapy or re-challenge.
- Hyperkalemia: High dosage of trimethoprim, as used in P. jirovecii pneumonia, induces a progressive but reversible increase of serum potassium in a substantial number of patients. Even recommended doses may cause hyperkalemia with underlying disorders of potassium metabolism, renal insufficiency, or drugs known to induce hyperkalemia; close monitoring of serum potassium is warranted.
- Hyponatremia: Severe and symptomatic hyponatremia can occur, particularly in the treatment of P. jirovecii pneumonia. Evaluation for hyponatremia and appropriate correction is necessary in symptomatic patients to prevent life-threatening complications.
- Crystalluria: Adequate fluid intake and urine output are needed throughout therapy.
- Idiosyncratic Reactions: Patients who are "slow acetylators" may be more prone to idiosyncratic reactions to sulfonamides.
- Sulfonamide cross-sensitivity: Chemical similarity to acetazolamide, thiazides, oral hypoglycemics, and goitrogens means cross-sensitivity may exist with those agents.
- Laboratory Tests: Complete blood counts and clinical chemistry testing should be done frequently. Perform urinalyses and renal function tests during therapy, particularly for those patients with impaired renal function. Discontinue BACTRIM if a significant electrolyte abnormality, renal insufficiency or reduction in the count of any formed blood element is noted.
- Drug Interactions: Avoid coadministration of BACTRIM with drugs that are substrates of CYP2C8 and 2C9 or OCT2. Avoid concurrent use with diuretics, methotrexate, cyclosporine, indomethacin, pyrimethamine, amantadine and angiotensin converting enzyme inhibitors. In elderly patients receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported, and marked but reversible nephrotoxicity has been reported with cyclosporine in renal transplant recipients.
- Potential for BACTRIM to Affect Other Drugs: It has been reported that BACTRIM may prolong the prothrombin time with warfarin. BACTRIM increased the phenytoin half-life by 39%, and can increase digoxin levels, especially in elderly patients. Increased dofetilide concentrations may cause serious ventricular arrhythmias, and trimethoprim raises procainamide and NAPA levels with further QTc prolongation. The efficacy of tricyclic antidepressants can decrease, and zidovudine has potential for additive myelotoxicity.
Common Side Effects
The most common adverse reactions are gastrointestinal disturbances (nausea, vomiting, anorexia) and allergic skin reactions (such as rash and urticaria). Fatalities and serious adverse reactions have occurred, including Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, AFND, AGEP, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias, acute and delayed lung injury, anaphylaxis and circulatory shock. Conjunctival and scleral injection is listed among the allergic reactions. Other reported reactions include thrombocytopenia, neutropenia, hemolytic and megaloblastic anemia, methemoglobinemia, renal failure, interstitial nephritis, crystalluria, hyperkalemia, hyponatremia, metabolic acidosis, hypoglycemia, aseptic meningitis, convulsions, peripheral neuritis, ataxia, vertigo, tinnitus, headache and QT prolongation.
Pregnancy: Some epidemiologic studies suggest an association between first trimester exposure and an increased risk of congenital malformations, particularly neural tube defects, cardiovascular abnormalities, urinary tract defects, oral clefts, and club foot, while other epidemiologic studies did not detect statistically significant associations. In rats, oral doses of 533 mg/kg sulfamethoxazole or 200 mg/kg trimethoprim produced cleft palates, and some rabbit studies showed increased fetal loss with trimethoprim at 6 times the human therapeutic dose. Because it may interfere with folic acid metabolism, BACTRIM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: Levels of sulfamethoxazole and trimethoprim in breast milk are approximately 2-5% of the recommended daily dose for infants over 2 months of age. Caution should be exercised when BACTRIM is administered to a nursing woman, especially when breastfeeding jaundiced, ill, stressed, or premature infants, because of the potential risk of bilirubin displacement and kernicterus.
Contraindicated in infants under 2 months of age.